



Gender:

Vandana lal Dr. Vandana Lal M.D (PATH), IFCAP

Name : Mrs. SHAKUNTALA P LOYALKA

295989685 Lab No.

Age: 81 Years

Collected Received **Female**

22/11/2020 10:43:00AM 22/11/2020 11:01:44AM

Reported

25/11/2020 10:23:11AM

A/c Status P Ref By: Dr. PUSHPENDRA GARG Report Status

Test Name Swasthfit Total - Iron Check	Results	Units	Bio. Ref. Interval
IRON STUDIES MONITORING PANEL			
Iron	37.00	μg/dL	50.00 - 170.00
Total Iron Binding Capacity (TIBC)	356.00	μg/dL	250.00 - 425.00
Transferrin Saturation	10.39	%	15.00 - 50.00
Ferritin	64.60	ng/mL	10.00 - 291.00

Comment

Iron is an essential trace mineral element which forms an important component of hemoglobin, metallocompounds and Vitamin A. Deficiency of iron, leads to microcytic hypochromic anemia. The toxic effects of iron are deposition of iron in various organs of the body and hemochromatosis.

Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from the gut to storage sites in the bone marrow. In iron deficiency anemia, serum iron is reduced and TIBC increases.

Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of Transferrin.

Ferritin appears to be in equilibrium with tissue ferritin and is a good indicator of storage iron in normal subjects and in most disorders. In patients with some hepatocellular diseases, malignancies and inflammatory diseases, serum ferritin is a disproportionately high estimate of storage iron because serum ferritin is an acute phase reactant. In such disorders iron deficiency anemia may exist with a normal serum ferritin concentration. In the presence of inflammation, persons with low serum ferritin are likely to respond to iron therapy.

THYROID PROFILE,TOTAL, SERUM (CLIA)			
T3, Total	1.37	ng/mL	0.40 - 1.81
T4, Total	11.30	μg/dL	5.01 - 12.45
TSH	2.99	μIU/mL	0.35 - 5.50



Page 1 of 19





Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

: 295989685 Age: 8

Age: 81 Years

Ref By: Dr. PUSHPENDRA GARG

Gender: Female

Collected Received 22/11/2020 10:43:00AM 22/11/2020 11:01:44AM

Reported

: 25/11/2020 10:23:11AM

Report Status : Final

Test Name Results Units Bio. Ref. Interval

Note

Lab No.

A/c Status : P

- 1. TSH levels are subject to circadian variation, reaching peak levels between 2 4.a.m. and at a minimum between 6-10 pm . The variation is of the order of 50% . hence time of the day has influence on the measured serum TSH concentrations.
- 2. Alteration in concentration of Thyroid hormone binding protein can profoundly affect Total T3 and/or Total T4 levels especially in pregnancy and in patients on steroid therapy.
- 3. Unbound fraction (Free,T4 /Free,T3) of thyroid hormone is biologically active form and correlate more closely with clinical status of the patient than total T4/T3 concentration
- 4. Values <0.03 uIU/mL need to be clinically correlated due to presence of a rare TSH variant in some individuals







Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

295989685 Lab No.

A/c Status : P

Age: 81 Years

Ref By: Dr. PUSHPENDRA GARG

Gender: **Female** Collected Received 22/11/2020 10:43:00AM

22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM Reported

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
LIVER & KIDNEY PANEL, SERUM			
Bilirubin Total (DPD)	0.58	mg/dL	0.20 - 1.10
Bilirubin Direct	0.14	mg/dL	<0.20
Bilirubin Indirect (Calculated)	0.44	mg/dL	<1.10
AST (SGOT) (IFCC without P5P)	24	U/L	<35
ALT (SGPT) (IFCC without P5P)	15	U/L	<35
GGTP (IFCC)	33	U/L	<38
Alkaline Phosphatase (ALP) (IFCC-AMP)	130	U/L	30 - 120
Total Protein (Biuret)	7.09	g/dL	6.40 - 8.10
Albumin (BCG)	3.92	g/dL	3.20 - 4.60
A: G Ratio (Calculated)	1.24		0.90 - 2.00
Urea (Urease UV)	17.67	mg/dL	17.00 - 43.00
Creatinine (Modified Jaffe,Kinetic)	0.62	mg/dL	0.51 - 0.95



Page 3 of 19







Name : Mrs. KALA LOYALKA

Lab No. : 295989685

A/c Status : P

Age: 81 Years

Ref By: Dr. PUSHPENDRA GARG

Gender: Female

Collected Received Reported : 22/11/2020 10:43:00AM : 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

Report Status : Final

Test Name Uric Acid (Uricase)	Results 2.69	Units mg/dL	Bio. Ref. Interval 2.60 - 6.00
Calcium, Total (Arsenazo III)	8.96	mg/dL	8.80 - 10.20
Phosphorus (Molybdate UV)	3.37	mg/dL	2.80 - 4.00
Sodium (Indirect ISE)	134.00	mEq/L	136.00 - 146.00
Potassium (Indirect ISE)	4.10	mEq/L	3.50 - 5.10
Chloride (Indirect ISE)	92.00	mEq/L	101.00 - 109.00







Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

Lab No.

A/c Status ;

295989685 Age:

Age: 81 Years

Ref By: Dr. PUSHPENDRA GARG

Gender: Female

Collected Received 22/11/2020 10:43:00AM

Reported

: 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
COMPLETE BLOOD COUNT;CBC (Electrical Impedence,Manual)			
Hemoglobin	15.90	g/dL	11.50 - 15.00
Packed Cell Volume (PCV)	47.60	%	36.00 - 46.00
RBC Count	5.27	mill/mm3	3.80 - 4.80
MCV	90.00	fL	80.00 - 100.00
MCH	30.10	pg	27.00 - 32.00
MCHC	33.40	g/dL	32.00 - 35.00
Red Cell Distribution Width (RDW)	13.10	%	11.50 - 14.50
Total Leukocyte Count (TLC)	9.00	thou/mm3	4.00 - 10.00
Differential Leucocyte Count (DLC)			
Segmented Neutrophils	68.30	%	40.00 - 80.00
Lymphocytes	25.80	%	20.00 - 40.00
Monocytes	4.60	%	2.00 - 10.00
Eosinophils	0.60	%	1.00 - 6.00
Basophils	0.70	%	<2.00
Absolute Leucocyte Count			
Neutrophils	6.15	thou/mm3	2.00 - 7.00
Lymphocytes	2.32	thou/mm3	1.00 - 3.00
Monocytes	0.41	thou/mm3	0.20 - 1.00
Eosinophils	0.05	thou/mm3	0.02 - 0.50
Basophils	0.06	thou/mm3	0.01 - 0.10
Platelet Count	254.0	thou/mm3	150.00 - 450.00



Page 5 of 19







Name : Mrs. KALA LOYALKA

295989685

Age: 81 Years

Gender: Female

Collected Received 22/11/2020 10:43:00AM

Reported

22/11/2020 11:01:44AM 25/11/2020 10:23:11AM

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
Mean Platelet Volume (MPV)	8.40	fL	6.50 - 12.00

Note

Lab No.

A/c Status

 As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood

Ref By: Dr. PUSHPENDRA GARG

2. Test conducted on EDTA whole blood







Dr. Vandana Lal M.D (PATH), IFCAP

Name Mrs. KALA LOYALKA

Collected

22/11/2020 10:43:00AM

Lab No.

295989685

Gender: **Female** Received Reported

22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

A/c Status

Ref By: Dr. PUSHPENDRA GARG

Age: 81 Years

Report Status : Final

Test Name	Results	Units	Bio. Ref. Interval
HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD (HPLC)			
HbA1c Estimated average glucose (eAG)	6.1 128	% mg/dL	

Interpretation

As per American	Diabetes Association (ADA)
Reference Group	HbA1c in %
Non diabetic adults >=18 years	4.0 - 5.6
At risk (Prediabetes)	5.7 - 6.4
Diagnosing Diabetes	>= 6.5
Therapeutic goals for glycemic control	< 7.0

Note

- 1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled
- 2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate
- 3. Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the A1C result does not correlate with the patient's blood glucose levels
- 4. In patients with HbA1c level between 7-8%, Glycemark (1,5 Anhydroglucitol) test may be done to identify those with more frequent and extreme hyperglycemic excursions

Comments

HbA1C reflects average glycemia over approximately 3 months, the test is the major tool for assessing glycemic control and has strong predictive value for diabetes complications. Thus, HbA1C testing should be performed routinely in all patients with diabetes - at initial assessment and as part of continuing care.



Page 7 of 19





Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

Lab No.

A/c Status

295989685 Age: 81 Years

Gender: Female

Ref By: Dr. PUSHPENDRA GARG

Collected Received 22/11/2020 10:43:00AM 22/11/2020 11:01:44AM

Reported

: 25/11/2020 10:23:11AM

Report Status : Final

Test Name Results Units Bio. Ref. Interval Measurement approximately every 3 months determines whether patients' glycemic targets have been reached and maintained. The frequency of A1C testing should depend on the clinical situation, the treatment regimen, and the clinician's judgement.

ADA Recommendations for HbA1c testing

- 1. Perform the A1C test at least two times a year in patients who are meeting treatment goals (and who have stable glycemic control)
- Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic goals

Factors that Interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements

Factors that affect interpretation of HbA1c Results: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c







Dr. Vandana Lal M.D (PATH), IFCAP

Name Mrs. KALA LOYALKA

295989685 Lab No.

Age: 81 Years

Female

Collected Received : 22/11/2020 10:43:00AM

Reported

: 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

Ref By: Dr. PUSHPENDRA GARG A/c Status **Report Status** : Final

Gender:

Test Name	Results	Units	Bio. Ref. Interval
RETICULOCYTE COUNT, WHOLE BLOOD (Manual)	0.90	%	0.50 - 2.50
GLUCOSE, FASTING (F), PLASMA (Hexokinase)	116.00	mg/dL	70.00 - 100.00
FOLATE (FOLIC ACID), SERUM @ (CLIA)	>24.00	ng/mL	>5.38

Interpretation

	RESULT IN ng/mL	REMARKS
	<3.37	Deficient
3.38-5.38		Indeterminate
	>5.38	Normal

Note

- 1. Drugs like Methotrexate & Leucovorin interfere with folate measurement
- 2. To differentiate vitamin B12 & folate deficiency, measurement of Methyl malonic acid in urine & serum Homocysteine level is suggested
- 3. Risk of toxicity from folic acid is low as it is a water soluble vitamin regularly excreted in urine

Comments

Folate plays an important role in the synthesis of purine & pyrimidines in the body and is important for the maturation of erythrocytes. It is widely available from plants and to a lesser extent organ meats, but more than half the folate content of food is lost during cooking. Folate deficiency is commonly prevalent in alcoholic liver disease, pregnancy and the elderly. It may result from poor intestinal absorption, nutrition deficiency, excessive demand as in pregnancy or in malignancy and in response to certain drugs like Methotrexate & anticonvulsants.

Decreased Levels

Megaloblastic anemia, Infantile hyperthyroidism, Alcoholism, Malnutrition, Scurvy, Liver disease, B12 deficiency, dietary amino acid excess, adult Celiac disease, Tropical Sprue, Crohn's disease, Hemolytic anemias, Carcinomas, Myelofibrosis, vitamin B6 deficiency, pregnancy, Whipple's disease, extensive intestinal resection and severe exfoliative dermatitis



Page 9 of 19





Vandana lal Dr. Vandana Lal M.D (PATH), IFCAP

Name Mrs. KALA LOYALKA

Gender:

: 22/11/2020 10:43:00AM

Lab No.

295989685 Age: 81 Years **Female**

Collected Received Reported

: 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

Ref By: Dr. PUSHPENDRA GARG A/c Status

Report Status : Final

Test Name Results Units Bio. Ref. Interval 211.00 - 911.00 VITAMIN B12; CYANOCOBALAMIN, SERUM 769.00 pg/mL (CLIA)

Notes

- Interpretation of the result should be considered in relation to clinical circumstances.
- 2. It is recommended to consider supplementary testing with plasma Methylmalonic acid (MMA) or plasma homocysteine levels to determine biochemical cobalamin deficiency in presence of clinical suspicion of deficiency but indeterminate levels. Homocysteine levels are more sensitive but MMA is more specific
- 3. False increase in Vitamin B12 levels may be observed in patients with intrinsic factor blocking antibodies, MMA measurement should be considered in such patients
- 4. The concentration of Vitamin B12 obtained with different assay methods cannot be used interchangeably due to differences in assay methods and reagent specificity

VITAMIN D, 25 - HYDROXY, SERUM 58.58 nmol/L (Chemiluminescence)

Interpretation

LEVEL 	REFERENCE RANGE IN nmol/L	COMMENTS
Deficient	< 50 	High risk for developing bone disease
Insufficient 	 50-74 	Vitamin D concentration Which normalizes Parathyroid hormone concentration
Sufficient	75-250 	Optimal concentration for maximal health benefit
Potential intoxication	>250 	 High risk for toxic

Note

- The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
- 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.



Page 10 of 19





Dr. Vandana Lal
M.D (PATH), IFCAP
Chief of Pathology
SHIROMANI AWARD WANNER

Name : Mrs. KALA LOYALKA

295989685

Art Death Sale To Best Death

Age: 81 Years Gender:

Collected Received Reported : 22/11/2020 10:43:00AM : 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

A/c Status : P Ref By : Dr. PUSHPENDRA GARG Report Status : Final

Test Name Results Units Bio. Ref. Interval

Female

Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.

• It shows seasonal variation, with values being 40-50% lower in winter than in summer.

• Levels vary with age and are increased in pregnancy.

• A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

Comments

Lab No.

Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

Decreased Levels

- Inadequate exposure to sunlight
- Dietary deficiency
- Vitamin D malabsorption
- Severe Hepatocellular disease
- · Drugs like Anticonvulsants
- · Nephrotic syndrome

Increased levels

Vitamin D intoxication







Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

Lab No. : 295989685

Age: 81 Years

Female

Collected Received : 22/11/2020 10:43:00AM

Received Reported : 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

A/c Status : P Ref By : Dr. PUSHPENDRA GARG Report Status : Final

Gender:

Test Name	Results	Units	Bio. Ref. Interval
LIPID SCREEN, SERUM			
Cholesterol, Total (CHO-POD)	150.00	mg/dL	<200.00
Triglycerides	92.00	mg/dL	<150.00
(GPO-POD)			
HDL Cholesterol (Enzymatic Immunoinhibition)	48.00	mg/dL	>50.00
LDL Cholesterol, Calculated	83.60	mg/dL	<100.00
VLDL Cholesterol,Calculated	18.40	mg/dL	<30.00
Non-HDL Cholesterol (Calculated)	102	mg/dL	<130

Interpretation

REMARKS	TOTAL CHOLESTEROL in mg/dL	TRIGLYCERIDE in mg/dL	LDL CHOLESTEROL in mg/dL	NON HDL CHOLESTEROL in mg/dL
Optimal	<200	<150	<100	<130
Above Optimal			100-129	130 - 159
Borderline High	200-239	150-199	130-159	160 - 189
High	>=240	200-499	160-189	190 - 219
Very High	-	>=500	>=190	>=220

Note

- 1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL& LDL Cholesterol.
- 2. NLA-2014 recommends a complete lipoprotein profile as the initial test for evaluating cholesterol.



Page 12 of 19





Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

A Led Postskiphs Druket Postskipels Druket Postskipels

Collected : 22/11/2020 10:43:00AM

Lab No. : 295989685

Gender: Female

Received : 22/11/2020 11:01:44AM Reported : 25/11/2020 10:23:11AM

: Final

A/c Status : P Ref By : Dr. PUSHPENDRA GARG Report Status

Age: 81 Years

Test Name Results Units Bio. Ref. Interval

Friedewald equation to calculate LDL cholesterol is most accurate when Triglyceride level is < 400 mg/dL. Measurement of Direct LDL cholesterol is recommended when Triglyceride level is > 400 mg/dL

- NLA-2014 identifies Non HDL Cholesterol(an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants)along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
- 5. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved
- 6. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

Treatment Goals as per Lipid Association of India 2016

RISK CATEGORY	TREA	TMENT GOAL	CONSIDER THERAPY	
CATEGORY	LDL CHOLESTEROL (LDL-C)(mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)	LDL CHOLESTEROL (LDL-C)(mg/dL)	NON HDL CHLOESTEROL (NON HDL-C) (mg/dL)
Very High	<50 		>=50	>=80
High	<70	<100	>=70	>=100
Moderate	<100	<130	>=100	>=130
Low	<100	<130	>=130*	>=160*

*In low risk patient, consider therapy after an initial non-pharmacological intervention for at least 3 months







Dr. Vandana Lal M.D (PATH), IFCAP

Name Mrs. KALA LOYALKA

Age: 81 Years

Received

: 22/11/2020 10:43:00AM

: 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

A/c Status

Lab No.

Test Name

295989685

Gender:

Ref By: Dr. PUSHPENDRA GARG

Female

Reported **Report Status**

Collected

: Final

Results Units Bio. Ref. Interval

INTERLEUKIN-6 (IL-6) MINI PANEL (ECLIA, Immunoturbidimetry)			
(IL-6) *	5.00	pg/mL	<4.4
D-Dimer , Quantitative @	0.71	mg/L FEU	<0.50

Note

- 1. Patient samples may contain heterophilic antibodies or mouse monoclonal antibodies that could react in immunoassays to give a falsely elevated or depressed result.
- 2. Results should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.
- 3. Patients receiving Biotin therapy in high doses (>5mg/day) should not be tested for at least 8 hours after the last dose.
- Test conducted in Plasma.

Comment

Symptoms of SARS-CoV-2 (COVID-19) vary from mild fever to ARDS complicating diagnosis, prognosis, and monitoring. Hence it is vital to ascertain a patient's condition in a timely manner. Biomarkers are quantitative measurements used clinically for many conditions reflecting pathological development. When assessing a patient with COVID-19 infection, biomarkers can be useful to clinicians in starting treatment and close monitoring.

C-REACTIVE PROTEIN; CRP, SERUM *	19.29	mg/L	<5.00
(Immunoturbidimetry)			

Comments

CRP is an acute phase reactant which is used in inflammatory disorders for monitoring course and effect of therapy. It is most useful as an indicator of activity in Rheumatoid arthritis, Rheumatic fever, tissue injury or necrosis and infections. As compared to ESR, CRP shows an earlier rise in inflammatory disorders which begins in 4-6 hrs, the intensity of the rise being higher than ESR and the recovery being earlier than ESR. Unlike ESR, CRP levels are not influenced by hematologic conditions like Anemia, Polycythemia etc.

LDH;LACTATE DEHYDROGENASE, SERUM @	236.00	U/L	<247.00
(IFCC)			

Comments

Lactate dehydrogenase (LDH) is a nonspecific enzyme found in most organs. Highest concentrations are found in liver, heart, kidney and blood cells. LDH measurements are used in the diagnosis and treatments of

* Not in NABL scope



Page 14 of 19



Hrw.i Ll (Hony) Brig. Dr. Arvind Lal M.B.B.S., D.C.P. The Market Production of the Pro-MR HONOGRAPH OF THE PRODUCT OF INDIA Vandana lal Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

295989685

Lab No.

De Leit PostiLista De Leit Postil

Age: 81 Years

Female

Collected Received

: 22/11/2020 10:43:00AM

Received : 22/11/2020 11:01:44AM Reported : 25/11/2020 10:23:11AM

A/c Status : P Ref By : Dr. PUSHPENDRA GARG Report Status : Final

Test Name Results Units Bio. Ref. Interval

liver diseases like Acute viral hepatitis, Cirrhosis & Metastatic carcinoma; Cardiac diseases like Myocardial infarction; Tumors of lungs / kidneys & Hematologic disorders like Megaloblastic anemia & Hemolytic anemia.

Gender:

* Not in NABL scope



Page 15 of 19







Name : Mrs. KALA LOYALKA

CONTRACTOR AND AND AND

Collected

: 22/11/2020 10:43:00AM

Lab No.

Toot Name

295989685

Gender: Female

Received Reported : 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM

A/c Status :

THE REAL PROPERTY.

Ref By : Dr. PUSHPENDRA GARG

Age: 81 Years

Report Status : Final

23/11/2020 10.23.11AII

Results Units Bio. Ref. Interval

Test Name	Results	Units	Bio. Ref. Interval
URINE EXAMINATION, ROUTINE; URINE, R/E (Dipstick, Microscopy)			
Physical			
Colour	Pale Yellow		Pale yellow
Specific Gravity	1.010		1.001 - 1.030
рН	6.5		5.0 - 8.0
Chemical			
Proteins	Negative		Negative
Glucose	Negative		Negative
Ketones	Negative		Negative
Bilirubin	Negative		Negative
Urobilinogen	Negative		Negative
Leucocyte Esterase	Negative		Negative
Nitrite	Negative		Negative
Microscopy			
R.B.C.	Negative		0.0 - 2.0 RBC/hpf
Pus Cells	0-1 WBC/HPF		0-5 WBC / hpf
Epithelial Cells	2-3 Epi Cells/hpf		0.0 - 5.0 Epi
Casts	None seen		cells/hpf None seen/Lpf
Crystals	None seen		None seen
Others	None seen		None seen



Page 16 of 19



(Hony) Brig. Dr. Arvind Lal M.B.B.S., D.C.P. Padlma Ghri FMR HONOBART PERSONNI OF INDU Dr. Vandana Lal M.D (PATH), IFCAP Chief of Pathology

Name : Mrs. KALA LOYALKA

295989685

Lab No.

- NALIN Problem De Las Problem De Las Problems De

Gender:

Received : 22/11/2020 11:01:44AM Reported : 25/11/2020 10:23:11AM

: 22/11/2020 10:43:00AM

A/c Status : P Ref By : Dr. PUSHPENDRA GARG

Age: 81 Years

Report Status : Final

Collected

Test Name Results Units Bio. Ref. Interval

IMPORTANT INSTRUCTIONS

Female

*Test results released pertain to the specimen submitted.*All test results are dependent on the quality of the sample received by the Laboratory.

*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician.*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.*Test results may show interlaboratory variations.*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. *Contact customer care Tel No. +91-11-39885050 for all queries related to test results.

(#) Sample drawn from outside source.



Page 17 of 19







Mrs. KALA LOYALKA Name

Lab No. 295989685 Age: 81 Years

Female

Collected Received

22/11/2020 10:43:00AM

22/11/2020 11:01:44AM 25/11/2020 10:23:11AM Reported

Ref By: Dr. PUSHPENDRA GARG A/c Status **Report Status** : Final

Test Name Results Units Bio. Ref. Interval

Gender:

CULTURE, URINE @

(Conventional culture, Automated Identification & Sensitivity)

Type of Specimen:

Result :- No Aerobic pyogenic organism grown

Dr Anil Arora MD, Pathology

HOD Hematology & Immunohematology NRL - Dr Lal PathLabs Ltd Dr Aniana Mittal MD, Pathology Consultant Pathologist

Dr Lal PathLabs Ltd

Dr.Kamal Modi MD, Biochemistry Consultant Biochemist NRL - Dr Lal PathLabs Ltd Dr Ritu Nayar

Deputy HOD - Microbiology & Serology NRL - Dr Lal PathLabs Ltd

MD, Microbiology

Dr Himangshu Mazumdar MD, Biochemistry Senior Consultant - Clinical Chemistry & Biochemical Genetics

National Head - Clinical Chemistry &

NRL - Dr Lal PathLabs Ltd

Dr Nimmi Kansal

MD, Biochemistry

Biochemical Genetics

NRL - Dr Lal PathLabs Ltd

Dr. Jasmine Kohli MD, Pathology Chief of Laboratory

Dr Lal PathLabs Ltd

Shalath Molik

Dr Shalabh Malik MD, Microbiology

National Head - Microbiology &

Serology

NRL - Dr Lal PathLabs Ltd

Dr Sunanda MD, Pathology Consultant

NRL - Dr Lal PathLabs Ltd

--End of report -



Page 18 of 19







Mrs. KALA LOYALKA Name

Lab No.

295989685

Age: 81 Years

Gender: **Female** Collected Received : 22/11/2020 10:43:00AM

: 22/11/2020 11:01:44AM : 25/11/2020 10:23:11AM Reported

Ref By: Dr. PUSHPENDRA GARG A/c Status : P Report Status : Final

Test Name Results Units Bio. Ref. Interval

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted.*All test results are dependent on the quality of the sample received by the Laboratory. *Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit request within 72 hours post reporting.*Test results may show interlaboratory variations.*The Courts/Forum at Delhi shall have exclusive jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. *Contact customer care Tel No. +91-11-39885050 for all queries related to test results. (#) Sample drawn from outside source

